产品说明书

Lisinopril Dihydrate

Print
Chemical Structure| 83915-83-7 同义名 : 赖诺普利二水合物 ;MK-521 dihydrate
CAS号 : 83915-83-7
货号 : A117961
分子式 : C21H35N3O7
纯度 : 99%
分子量 : 441.519
MDL号 : MFCD01698825
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 20 mg/mL(45.3 mM)，配合低频超声助溶
动物实验配方：
生物活性
靶点

  • ACE
描述 Lisinopri dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. Lisinopril is the only ACE inhibitor that exhibits a linear dose-response curve. Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy[3]. In all concentrations (25, 75 and 250 mg/l drinking water), lisinopril significantly increased PRA (plasma renin) and decreased ACE activities. Arterial blood pressure was decreased only in the group receiving high lisinopril concentration (Controls 119+/-10.27, Ld3 98+/-5.4 mm Hg)[4]. Systolic blood pressure (SBP) was normal in Wistar rats, SHR (spontaneously hypertensive rats) expressed hypertension and lisinopril normalized the SBP. Lisinopril normalized the increase in SBP and partly reversed the alterations of anxiety-like behaviour in SHR[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01936012 Healthy Not Applicable Completed - Indonesia ... 展开 >> PT Equilab International Jakarta, Indonesia, 12430 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.32mL

2.26mL

1.13mL

22.65mL

4.53mL

2.26mL
参考文献

[1]Andújar-Sanchez M, Jara-Perez V, et al. Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54.

[2]Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24.

[3]Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24

[4]Ozdemir HS, Aksulu HE, Karataş F, Ustündag B, Bingöl I. Long-term lisinopril dihydrate application decreases plasma noradrenaline but not adrenaline levels in chickens. Physiol Res. 2000;49(1):183-8

[5]Repova K, Aziriova S, Kovacova D, Trubacova S, Baka T, Kanska R, Barta A, Stanko P, Zorad S, Molcan L, Adamcova M, Paulis L, Simko F. Lisinopril reverses behavioural alterations in spontaneously hypertensive rats. Gen Physiol Biophys. 2019 May;38(3):265-270